参考文献/References:
[1] 刘胜文，肖群根，徐 钰，等. 经蝶手术治疗前后库欣病患
者代谢的研究[J]. 中华神经外科疾病研究杂志，2012，11
（6）：530-534.
[2] Kreitschmann-Andermahr I, Psaras T, Tsiogka M, et al.
From first symptoms to final diagnosis of Cushing's disease:
experiences of 176 patients [J]. Eur J Endocrinol, 2015,
172: 285-289.
[3] 马翔宇，张 鑫，李卫国，等. 神经内镜下经鼻蝶窦入路垂
体ACTH腺瘤切除术47例临床分析[J]. 中华神经外科杂
志，2014，30（10）：1012-1015.
[4] Hofmann BM, Hlavac M, Martinez R, et al. Long-term
results after microsurgery for Cushing disease: experience
with 426 primary operations over 35 years [J]. J Neurosurg,
2008, 108: 9-18.
[5] Nakayama S, Nishiyama M, Iwasaki Y, et al. Corticotropin-
releasing hormone (CRH) transgenic mice display hyperp-
hagia with increased Agouti-related protein mRNA in the
hypothalamic arcuate nucleus [J]. Endocr J, 2011, 58: 279-
286.
[6] Riebold M, Kozany C, Freiburger L, et al. A C-terminal
HSP90 inhibitor restores glucocorticoid sensitivity and
relieves a mouse allograft model of Cushing disease [J]. Nat
Med, 2015, 21: 276-280.
[7] Fleseriu M. Medical treatment of Cushing disease: new tar-
gets, new hope [J]. Endocrinol Metab Clin North Am, 2015,
44: 51-70.
[8] Occhi G, Regazzo D, Albiger NM, et al. Activation of the
dopamine receptor type-2 (DRD2) promoter by 9-cis reti-
noic acid in a cellular model of Cushing's disease mediates
the inhibition of cell proliferation and ACTH secretion
without a complete corticotroph-to-melanotroph transdiffe-
rentiation [J]. Endocrinology, 2014, 155: 3538-3549.
[9] van der Hoek, J Lamberts SW, Hofland LJ. The somatostatin
receptor subtype 5 in neuroendocrine tumours [J]. Expert
Opin Investig Drugs, 2010, 19: 385-399.
[10] de Bruin C, Pereira AM, Feelders RA, et al. Coexpression of
dopamine and somatostatin receptor subtypes in cortico-
troph adenomas [J]. J Clin Endocrinol Metab, 2009, 94:
1118-1124.
[11] Culler MD. Somatostatin-dopamine chimeras: a novel
pproach to treatment of neuroendocrine tumors [J]. Horm
Metab Res, 2011, 43: 854-857.
[12] Amaral FC, Torres N, Saggioro F, et al. MicroRNAs diffe-
rentially expressed in ACTH-secreting pituitary tumors [J].
J Clin Endocrinol Metab, 2009, 94: 320-323.
[13] Stilling G, Sun Z, Zhang S, et al. MicroRNA expression in
ACTH-producing pituitary tumors: up-regulation of micro-
RNA-122 and -493 in pituitary carcinomas [J]. Endocrine,
2010, 38: 67-75.
[14] Gentilin E, Tagliati F, Filieri C, et al. MiR-26a plays an
important role in cell cycle regulation in ACTH-secreting
pituitary adenomas by modulating protein kinase C delta [J].
Endocrinology, 2013, 154: 1690-1700.
[15] Kawashima ST, Usui T, Sano T, et al. P53 gene mutation in
an atypical corticotroph adenoma with Cushing's disease [J].
Clin Endocrinol (Oxf), 2009, 70: 656-657.
[16] Reincke M, Sbiera S, Hayakawa A, et al. Mutations in the
deubiquitinase gene USP8 cause Cushing's disease [J]. Nat
Genet, 2015, 47: 31-38.
[17] Perez-Rivas LG, Theodoropoulou M, Ferrau F, et al. The
gene of the ubiquitin-specific protease 8 is frequently
mutated in adenomas causing Cushing's disease [J]. J Clin
ndocrinol Metab, 2015, jc20151453.
[18] Ma ZY, Song ZJ, Chen JH, et al. Recurrent gain-of-function
USP8 mutations in Cushing's disease [J]. Cell Res, 2015,
25: 306-317.